VKTX 250411 25.50C(VKTX250411C25500) Stock Price Today

US OptionsDetailed Quotes

VKTX250411C25500

Watchlist

0.29
-0.24-45.28%

15min DelayClose Apr 7 16:00 ET

0.29High0.29Low

Intraday

5D
Daily

News

Viking Therapeutics Director Makes a Bold Stock Purchase!
TipRanksApr 2 22:02 ET
Insider Purchase: Director at $VKTX Buys 1,240 Shares
Quiver QuantitativeApr 2 18:31 ET
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Yahoo FinanceApr 2 04:40 ET
Viking Therapeutics (NasdaqCM:VKTX) Seals Manufacturing Deal as Stock Declines 11% Over The Past Month
Yahoo FinanceMar 31 13:50 ET
Analysts Conflicted on These Healthcare Names: Zentalis Pharmaceuticals (ZNTL) and Viking Therapeutics (VKTX)
TipRanksMar 31 03:00 ET · Ratings
SA Asks: Which Cardiology Drug Companies Could Be Takeout Candidates?
Seeking AlphaMar 29 14:00 ET

Comments

Jaguar8

Mar 26 19:15

NEWS

$Viking Therapeutics (VKTX.US)$
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint foc...